Improving early triple-negative breast cancer prediction
Part of Cancer clinical trials.
This study is part of a larger project collecting detailed genetic and other biological data from people with triple-negative breast cancer. The goal is to build better models to predict how the disease will progress and respond to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be already enrolled in the UPGRADE-TNBC study.
- This trial specifically looks at people with early-stage triple-negative breast cancer.
- You need to have completed or be undergoing the initial assessments required by the UPGRADE-TNBC study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses blood tests to look for signs of cancer returning early in women who had triple-negative breast cancer. If caught early, doctors can start treatment sooner.
This study helps doctors predict which patients will respond best to immunochemotherapy (a combination of immune-boosting and chemotherapy drugs) for early-stage triple-negative breast cancer. By understanding your tumor better before treatment, doctors may be able to personalize your care plan.
This study is for people with early-stage triple-negative breast cancer (TNBC) that has not been treated yet. Researchers want to see if tracking tumor DNA in your blood can help guide treatment decisions. You would receive standard chemotherapy and surgery, plus give blood samples.
This trial tests whether using blood tests and imaging during chemotherapy and immunotherapy can help guide treatment for early-stage triple-negative breast cancer. It aims to improve outcomes by adjusting treatment based on how the cancer responds.
This study looks for “biomarkers,” or tumor clues, that may help predict who benefits from checkpoint inhibitor immunotherapy in triple-negative breast cancer. It may help doctors choose the right treatment approach in the future, especially when chemotherapy is planned.
This study tests a new way to choose treatment for advanced triple-negative breast cancer, based on a special analysis of your tumor. The goal is to find a treatment that works better for your specific cancer type.
Hear when a new Triple -Negative Breast Cancertriple trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.